Purchase this article with an account.
Arun Singh, Mary Aronow, Charles Biscotti, Raymond Tubbs, Lynn Schoenfield, Pierre Triozzi; Prognostic FNAB of Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4216.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report experience with prognostic fine needle aspiration biopsy of uveal melanoma.
Prospective interventional series of 150 consecutive patients with uveal melanoma treated at the Cleveland Clinic Cole Eye Institute between May 2009 and August 2012. FNAB was performed with 25-gauge needle. Chromosome 3 status was assessed by FISH using both directly labeled Spectrum Green® and Spectrum Orange® enumeration probes for the alphacentromeric locus of chromosome 3 (CEP3). Cut off value of 20% was used to define monosomy fro chromosome 3.
41 eyes were enucleated, 102 treated with plaque radiation therapy and 7 treated by local resection. Enucleated eyes were subjected to transcleral FNAB in all cases. Patients undergoing plaque radiation therapy underwent trans corneal (6) transcleral (32) or trans vitreal biopsy (64) based upon tumor location. Overall, sample was adequate for FISH analysis in 135 eyes (90%). Eyes that underwent enucleation revealed greater proportion of monosomy 3 cells (67% vs 40%) respectively. 32 (53%) patients with monosomy 3 entered into an adjuvant treatment trial.
Prognostic biopsy FNAB for uveal melanoma with 25-gauge needle can yield sufficient samples in 90% of cases. High-risk cases identified by FISH FNAB can be recruited into an adjuvant treatment trial.
This PDF is available to Subscribers Only